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ABSTRACF For more than 40 years, it has been
appreciated that vitamin A is a critical regulator of
growth and differentiation of developing and adult
mammalian and avian skin. Vitamin A deficiency and
hypervitaminosis A cause disruption of normal cellu-
lar homeostatic mechanisms, resulting in impairment
of skin barrier function. More recent studies demon-
strating all-trans retinoic acid as the major biologi-
cally active form of vitamin A, and nuclear retinoid
receptors as the major mediators of all-trans retinoic
acid actions, have provided exciting new insights into
the molecular basis of vitamin A actions. These
recent insights have been the driving force for im-
portant advances in the many areas of retinoid re-
search made during the past 6 years. Nowhere has
this new knowledge been more extensively applied
than toward understanding the molecular basis of
retinoid physiology and pharmacology in skin. This
article will review these recent findings and attempt
to synthesize their meaning to provide a view into the
mechanisms whereby retinoids participate in regula-
tion of skin function.-Fisher, G. J., Voorhees, J. J.
Molecular mechanisms of retinoid actions in skin.
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BACKGROUND
Morphology of human skin
The two major compartments of human skin are epider-
mis and dermis (Fig. 1, left panel). The major cell type
in the epidermis is the keratinocyte. Keratinocytes in the
bottom (basal) layer undergo cell division, migrate up-
ward through suprabasal layers, and undergo terminal
differentiation to form the protective barrier. Melanocytes,
which synthesize pigment and give skin its color, also re-
side in the bottom layer of the epidermis. The epidermis
is separated from the dermis by the basement membrane
zone composed primarily of type IV and type VII colla-
gens, laminin, entactin, fibronectin, and proteoglycans.
The dermis is primarily extracellular matrix, composed of
type I and type III collagens, and elastin, which are syn-
thesized by dermal fibroblasts. Blood supply to the skin
occurs via capillaries in the dermis. A single topical ap-
plication of 0.1% all-trans retinoic acid (tRA)2 for 4 days
stimulates keratinocyte proliferation, increasing the num-
bers of epidermal cell layers and increasing epidermal
thickness (1, 2) (Fig. 1, right panel). tRA also causes
characteristic compaction of the barrier and widening of
spaces between keratinocytes. Although, for a variety of
technical reasons, more is known about the effects of reti-
noids on epidermis than on dermis, cells in the dermis
are also important targets for retinoid actions in skin.
NUCLEAR RETINOID RECEPTORS AND THEIR
TARGET GENES IN SKIN
Transgemc mouse models
Retinoic acid receptors (RARs) and retinoid X receptors
(RXRs) are members of the steroid hormone receptor su-
perfamily of ligand-activated transcription factors (3).
RAR-ct, f, and y RXR-a, , and y bind as heterodimers
to specific DNA sequences (retinoic acid response ele-
ments, RARE) in regulatory regions of target genes (Fig.
2, upper panel). Binding of tRA by RAR-y activates the
heterodimeric complex (the RXRct ligand 9-cis retinoic
acid does not contribute to activation of liganded RAR-y
in human skin), thereby stimulating target gene transcrip-
tion by a process known as transactivation. Physiological
actions of retinoids are believed to be mediated primarily
through RARJRXR-mediated transactivation.
Targeted disruption of RARs, through homologous re-
combination, has been used as a genetic approach to elu-
cidate physiological functions of RARs in the mouse, as
reviewed in ref 4. The skin of mice null for either RAR-a
(5) or RAR-y (6) appears phenotypically normal. Disrup-
tion of both RAR-a and RAR-y, although resulting in se-
vere developmental defects in many organs, surprisingly
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does not significantly alter epidermal morphology (7).
However, additional functional and molecular charac-
terization of the skin of these mice is clearly required and
may reveal significant alterations not manifest at the mor-
phological level. In contrast, targeted overexpression of
dominant negative mutant RAR-a to mouse epidermis re-
sults in distinct phenotypic abnormalities. Overexpression
of mutated RAR-a in suprabasal keratinocytes results in
reduced barrier function due to defects in lipid deposi-
tion by keratinocytes undergoing terminal differentiation
(8). No generalized defects in programmed differentiation
of suprabasal keratinocytes are observed. Overexpression
of dominant negative mutant RAR-a in basal keratino-
cytes results in dramatic impairment of epidermal matu-
ration (9). Even though these results are indicative of
RAR involvement in normal skin development and func-
tion, caution must be exercised in their interpretation, as
the dominant negative RAR-ct mutants that were used are
capable of heterodimerizing with RXRs. Therefore,
through sequestration of RXRs, the mutant RAR-a could
interfere with functions of other RXR heterodimeric part-
ners, in addition to RARs (see below). Thus, one cannot
conclude that the observed phenotypic alterations in skin
were due exclusively to interference with RAR function.
Figure 1. Histology of human skin treated with vehicle or 0.1% tRA.
The two major compartments of human skin are epidermis (#1) and
dermis (#6). The major cell type in the epidermis is the keratinocyte.
Keratinocytes in the bottom (basal) layer (#4) undergo cell division,
migrate upward through suprabasal layers (#3), and undergo terminal
differentiation to form the protective barrier (#2). Melanocytes, which
synthesize pigment and give skin its color, also reside in the bottom layer
of the epidermis (not apparent in these sections of skin). The epidermis
is separated from the dermis by the basement membrane zone (#5). The
dermis (#6) is primarily extracellular matrix, composed ofcollagens and
elastin that are synthesized by sparse dermal fibroblasts. Blood supply to
the skin occurs via capillaries (not apparent in thesesectionsof skin)in
thedermis.A singletopicalapplicationof0.1% tRA for4 days stimulates
keratinocyte proliferation, causing increased numbers of epidermal cell
layers and increased epidermal thickness (right panel). tRA also causes
characteristic compaction of the barrier,and widening of the spaces
between keratinocytes. #1: Epidermis (keratinocytes); #2: nonliving
barrier (cross-linked envelopes and lipids); #3: suprabasal keratinocyte
layers(differentiation);#4: basal keratinocytelayers(proliferation);#5:
dermoepidermal junction (basement membrane zone);#6: dermis (col-
lagen and fibroblasts.
Nuclear retinoid receptors
Human epidermis expresses transcripts for RAR-a,
RAR-y, RXR-a, and RXR- (10). Transcripts for RAR-
are low or undetectable, whereas RXR-’y mRNA is unde-
tectable. A similar pattern is seen in cultured human
keratinocytes and dermal fibroblasts (11). Unlike other
cell types, RAR- expression is not induced by tRA in
human keratinocytes in vivo or in culture (11). This is
not due to failure of the RAR-32-RARE to function in
keratinocytes, because in transient transfections the iso-
lated RAR-2 RARE confers induction by tRA on a
chloramphenicol acetyltransferase (CAT) reporter (12). In
contrast to keratinocytes, RAR-3 is induced by tRA in
cultured human dermal fibroblasts (11, 13).
Using ligand binding and immunological assays, total
and individual RAR and RXR protein levels have also
been determined in human epidermis (14). Total RXR
protein levels are fivefold greater than RAR total protein
levels. Among RXR proteins, nearly 90% is RXR-a, with
RXR- minimally detectable and RXR-y undetectable.
Thus, among RAR proteins, nearly 90% is RAR-’y, with
approximately 10% RAR-ct and no detectable RAR4.
Relative levels of individual RXR and RAR proteins are
in good agreement with their apparent relative mRNA
levels. If RARs and RXRs are uniformly expressed in
epidermal cells, approximately 1800 RARs and 9400
RXRs will be present in each cell. Thus, RXRs do not
seem to be limiting for heterodimerization with RARs.
This assumes, however, that the number of different RXR
partners is limited and that they are expressed at levels
similar to, or less than, RARs (Fig. 2, lower panel). So
far, this appears to be the case in human epidermis. Lev-
els of RXR partners for which ligands are known, i.e.,
thyroid hormone receptor, vitamin D receptor, and perox-
isorne proliferator-activated receptor, appear to be rela-
tively low compared to RARs. Levels of other known
RXR partners such as LXR (15), NGFI-B (16), NURR1
(16), RIP14 (17), and RIP15 (17), and other unknown
orphan receptors that potentially might heterodimerize
with RXRs, in human skin, however, are not known. The
extent to which competition among nuclear receptors for
interaction with RXRs influences RAR-mediated re-
sponses in skin remains to be elucidated.
Retinoic acid receptor-y preferentially binds tRA
RARs in human epidermis bind all-trans and 9-cis reti-
noic acid with similar high affinity (14). Equilibrium dis-
sociation constants (Kd) for binding of these two ligands
by human epidermal RARs are similar to those reported
for recombinant RARs (0.2-0.7 nM) (18). Allenby et al.
(19) reported that although the off-rates for tRA binding
to RAR-a, RAR-f, and RAR-’y are similar, off-rates for
9-cts retinoic acid differ among the three RARs, with
RAR- the slowest and RAR-T the fastest. As a conse-
quence of this, in the presence of mixtures of all-trans
and 9-cts retinoic acid, RAR-’y strongly prefers tRA.
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RAR-y, in human skin nuclear extracts and intact epider-
mal cells, displays a similar strong preference for all-
trans vs. 9-cis retinoic acid. At ratios of up to 4 to 1
(9-c&s retinoic acid to tRA), no binding of 9-ci,s retinoic
acid is detectable. This is in clear distinction to RAR-a
in human skin, which when incubated with mixtures of
all-trans and 9-ci.s retinoic acid in differing ratios, binds
the two ligands in the same proportions as are present in
the mixtures.
These results suggest that only under conditions where
9-ci.s retinoic acid levels exceed tRA levels several fold
would 9-cis retinoic acid be able to activate RAR-y-medi-
ated responses in human skin. In normal human skin, 9-
cis retinoic acid levels are less than tRA levels (20), thus
precluding 9-cis retinoic acid as a physiological activator
of RAR-y. 9-cis Retinoic acid applied topically to human
skin is rapidly isomerized to tRA (20). The tRA formed
would be expected to displace any 9-ci,s retinoic acid
bound to RAR-’y. Because RAR-y comprises 90% of total
RARs in human skin, 9-cis retinoic acid probably serves
a minor, if any, role in regulating RAR-mediated re-
sponses in human skin either under physiological or
pharmacological conditions.
Retinoic acid receptor/retinoid X receptor
heterodimers
In gel shift studies, RARs and RXRs in nuclear extracts
from human skin and cultured keratinocytes bind exclu-
sively as heterodimers to RARE, DNA sequences com-
posed of hexameric direct repeats spaced by two (DR-2)
or five nucleotides (DR-5), and to retinoid X response
Figure 2. Functional interactions of retinoid receptors in human skin. Retinoic acid receptor-y
(RAR- and retinoid X receptor-a (RXRa) are the predominant retinoid receptors in human skin.
Top panel: RAR-’y and RXRa bind as heterodimers to specific DNA sequences (retinoic acid response
elements) in regulatory regions of target genes. Binding of tRA by RAR-y activates the heterodimeric
complex (the RXRa ligand 9-cis retinoic acid does not contribute to activation of liganded RAR-y in
human skin), thereby stimulating target gene transcription by a process known as transactivation.
Physiological actions of retinoids in skin are mediated primarily through RARIRXR-mediated trans-
activation. Middle panel: Retinoid receptors also interact with transcription factor AP-1, composed of
jun and fos proteins. AP-1 regulates transcription of many genes that participate in regulation of growth,
differentiation, and responses to stress (physiology). Disregulation of AP-1 is associated with malignant
transformation, inflammatory diseases states, and sun-induced skin aging. Interaction of retinoid
receptors with AP-1 is dependent on tRA, and the complex that is formed is unable to transactivate
either RARE or AP-1 response element (AP-1 RE) -containing genes (transrepression). For simplicity,
interaction between retinoid receptors and AP-1 is depicted as direct; although the exact nature of this
complex (or complexes) is not known, it is most likely indirect and involves additional protein
components. Transrepression of AP-1 appears to be a major mechanism of pharmacological anti-in-
flammatory and antiproliferative effects of retinoids. Lower panel: RXRa in skin also functions as a
heterodimeric partner with other members of the steroid receptor superfamily (R), including vitamin
D, thyroid hormone, and peroxisome proliferator-activated receptors. Thus, the interaction of RXR
with these nuclear receptors limits the ability of RXR to bind to RARs. Each heterodimeric complex
binds to specific hormone response elements (HRE) in target genes. Binding of cognate ligands (L) by
these receptors stimulates transactivation, which is further enhanced for certain receptors, but not
others, by the binding of 9-cis retinoic acid (9cRA) to RXRci
elements (RXRE), direct repeats spaced by one nucleo-
tide (DR-i) (12, 14, 21). The presence of either all-trans
or 9-cis retinoic acid has no effect on heterodimer DNA
binding. Nuclear extracts, prepared from keratinocytes
overexpressing RXRs, display RXR homodimer binding
to DR-i, and this binding is enhanced by 9-cit retinoic
acid (12). In keratinocytes, transcription of CAT reporter
genes regulated by RAREs (DR-2 or DR-5) is induced by
tRA, 9-cit retinoic acid, and the RAR-specific ligand
CD367, but not the RXR-specific ligand SR11237. In
contrast, transcription of an RXRE (DR-i) CAT reporter
in keratinocytes is not activated by any of the above ii-
gands. The inability of RARJRXR heterodimers to trans-
activate DR-i elements in keratinocytes is consistent
with results in other cell types, shown to be a conse-
quence of the orientation the heterodimer adopts on a
DR-i element (22). The RXRE reporter, however, is in-
duced by tRA (by isomerization to 9-cis retinoic acid), 9-
cit retinoic acid, and SR11237 (but not CD367) in
keratinocytes overexpressing RXRs, i.e., under conditions
that promote RXR homodimers. Thus, at their physiologi-
cal levels, RARs and RXRs in human skin and keratino-
cytes bind DR-2 and DR-S RAREs as heterodimers and
transactivate these elements in response to RAR, but not
RXR, ligands (Fig. 2, upper panel). Lack of RXR ho-
modimer formation and DR-i transactivation in human
keratinocytes is consistent with studies of mouse skin,
where topical application of SR11237 evokes no detect-
able response (23).
Retinoid receptor target genes
Several genes have been shown to be directly regulated
by RAREs through functional RAREs in their promoters
(24). Of these, the best characterized in human skin are
cellular retinoic acid binding protein II (CRABPII) (25,
26), cellular retinol binding protein (CRBP) (21), and
keratin 6 (27, 28). Each of these genes is induced in hu-
man skin by tRA application. The human CRABPII gene
contains a DR-5 RARE 5.6 kb upstream from the tran-
scriptional start site that confers transcriptional induction
by tRA (29). Thus, induction of CRABPII mRNA by syn-
thetic retinoids can be used as an indicator of specific
retinoid activity in human skin.
Although the human CRBP gene has not been charac-
terized, CRBP in rat (30) and mouse (3i) contains a
functional DR-2 RARE. In human skin, the kinetics and
retinoid dose dependence of CRBP mRNA induction par-
allel those for CRABPII, thus making it likely that tran-
scription of human CRBP, like its rodent counterparts, is
regulated by an RARE (21).
Keratin 6 normally is not expressed in human skin;
keratin 6 is expressed, however, in hyperproliferative
skin diseases and in response to retinoids. Only a limited
region of the human keratin 6 promoter has been charac-
terized (32). This region, however, is highly homologous
to the bovine keratin 6 promoter, which has been more
extensively studied (33). The bovine keratin 6 promoter
contains a functional RARE located 540 bp upstream of
the transcriptional start site. Although this region lies fur-
ther upstream than has yet been studied in the human
keratin 6 gene, it is likely that a homologous element is
present in the human keratin 6 promoter and accounts for
retinoid induction. The human and bovine keratin 6 pro-
moters also contain positive regulatory elements for tran-
scription factor AP-i (activator protein-i). This element
is probably responsible for keratin 6 induction in hyper-
proliferative skin conditions in which AP-1 is activated.
The AP-1 element in the keratin 6 promoter is function-
ally antagonized by RARs (i.e., transrepressed). In spite
of this, the net effect of retinoids is not inhibition of kera-
tin 6 expression, but rather induction, due to the RARE
in its promoter.
AP- 1 transrepression by retinoid receptors
Functional antagonism of AP-i by RARs, termed
transrepression, is not unique to regulation of keratin 6
expression. Transrepression is a widespread mechanism
for cross-talk between retinoid receptors and AP-i
(34-36). The molecular mechanism of transrepression is
believed to involve direct or indirect protein-protein in-
teractions between retinoid receptors and AP-i compo-
nents c-jun and c-fos, and/or competition between
retinoid receptors and APi, for a common factor (or fac-
tors) required for their activities (35, 36) (Fig. 2, middle
panel). Like transactivation, transrepression is dependent
on tRA. An example with considerable practical impor-
tance of transrepression has been described in the con-
text of molecular responses of skin to sunlight. Chronic
exposure to ultraviolet irradiation from the sun causes
premature skin aging, referred to as photoaging (37).
Photoaging is manifested by wrinkles, reduced elasticity,
fine lines, darkened and uneven pigmentation, and rough-
ness. The major histological features of photoaged skin
are evident in connective tissue (dermis) underlying the
epidermis. These include accumulation of disorganized
elastin-containing fibers and reduced content of type I
and type III procollagens in the extracellular matrix.
These findings have led to the conclusion that the cause
of photoaging is sun-induced dermal damage (37, 38).
This damage is likely mediated by destruction of the ex-
tracellular matrix of the dermis by matrix-degrading met-
alloproteinases (39).
Promoters for these metalloproteinases such as intersti-
tial collagenase, gelatinase B, and stromelysin I contain
AP-i response elements, which are necessary for gene
transcription. Exposure of human skin to doses of ultra-
violet irradiation equivalent to a few minutes of sunlight
up-regulates AP-i and induces metalloproteinase tran-
scripts, proteins, and activities (39). It is believed that
the ensuing dermal damage is not perfectly repaired, re-
sulting in an invisible scar. Accumulation of such solar
invisible scars, caused by repeated sunlight exposure
over many years, eventuates in visible solar scars, which
are responsible for photoaging (39).
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Treatment of human skin with tRA or its metabolic
precursor all-trans retinol prior to ultraviolet irradiation
exposure blocks AP-1 activation and induction of intersti-
tial collagenase, gelatinase B, and stromelysin I (39). In-
hibition of matrix metalloproteinase induction by tRA
presumably occurs through transrepression of AP-i, be-
cause tRA prevents ultraviolet irradiation-induced AP-1
activation (39). These data suggest that tRA and all-trans
retinol may be beneficial for prevention of photoaging, al-
though this has not yet been tested in prospective clinical
trials designed to detect prevention. In addition, tRA has
been shown to improve the appearance of photoaged skin
(40). This may well occur, at least in part, as a result of
restitution by tRA of type I collagen synthesis, which is
reduced in photoaged skin (4i-43). Thus, tRA, acting
through two apparently separate mechanisms, may be
useful both for preventing photoaging and for repairing
photoaging once it has occurred.
RETINOID METABOUSM IN HUMAN SKIN
Retinol esterffication
Retinyl esters and n-carotene taken in from the diet are
converted to all-trans retinol in the intestine and stored
in the liver after reconversion to retinyl esters. Retinol
released from the liver is transported in the circulation
complexed to plasma retinol binding protein. Circulating
retinol apparently is taken up by skin cells through pas-
sive diffusion. In human skin, all-trans retinol is metabo-
lized to at least four important products: retinyl esters,
14-hydroxy-4, 14-retro-retinol, all-trans 3,4-didehydroreti-
nol (and its ester), and tRA. Among these three metabo-
lites, retinyl ester levels are greatest. Retinyl esters
function as a storage form of retinol. Their hydrolysis
yields free retinol, which can be further metabolized.
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Figure 3. Autoregulation of tRA (RA) metabolism inhuman skin. All-trans retinol (tROL), taken up from the circulation or applied externally,
is bound by cellular retinol binding protein (CRBP) in keratinocytes. tROL bound to CRBP is eitheresterified to retinyl esters (tROL ESTERS),
catalyzed by lecithin:retinol acyltransferase (LRAT) or sequentially oxidized to all-trans retinaldehyde (IRAL), catalyzed by retinol
dehydrogenase (tROL DeHase), and then to all-trans retinoic acid (tRA), which is catalyzed by retinaldehyde dehydrogenase (tRAL DeHase).
tRA, synthesized from tROL or applied topically, binds to cellular retinoic acid binding protein-LI (CRABP-IL). tRA bound to CRABP-LL is
either hydroxylated by tRA 4-hydroxylase (tRA 4-Ollase) to 4-hydroxy tRA (4-OH tRA), which has only weak biological activity, or enters
the nucleus where it binds to and activates the RAR-y component of retinoid X receptor (RXRa)/retinoic acid receptor (RAR-y) heterodimers.
Activation of RXRWRAR-y by LRA stimulates transcription of genes containing retinoic acid response elements (RARE) in their promoters.
tRA induces CRBP, CRABP-II, LRAT, and tRA 4-OHase (each shown in red) in human skin, and thereby tightly regulates its own level.
CRBP and CRABP-lI contain RAREs in their promoters, and therefore their transcription is directly stimulated by RXRIRAR. The mechanism
(direct or indirect) through which tRA induces LRAT and tRA 4-OHase is not known (signified by dashed arrows), but may also involve
RXR/RAR-mediated gene transcription.
Topical treatment of human skin for 24 h with all-trans
retinol or all-trans retinaldehyde increases retinyl ester
levels greater than 10-fold in the living cell layers (44).
Skin expresses both lecithin:retinol acyltransferase
(LRAT) and acyl CoA:retinol acyltransferase (ARAT) ac-
tivities, the two enzymes known to catalyze retinyl ester
synthesis (45, 46). The normally low LRAT activity of
cultured keratinocytes is induced by retinoids, probably
via RARs, within 12 h (45) (Fig. 3). Induction of LRAT
activity by retinoids increases retinyl ester formation and
reduces tRA biosynthesis (45). Under these conditions,
inhibition of LRAT by phenylmethylsulfonyl fluoride re-
stores tRA synthesis. Thus, reduction of tRA synthesis in
skin occurs through increased competition for all-trans
retinol between LRAT and retinol dehydrogenase rather
than by inhibition of tRA synthesis per se.
Regulation of LRAT activity by retinoids provides a
mechanism of autoregulation of tRA synthesis through
substrate availability. Under conditions of retinoid suffi-
ciency, all-trans retinol esterification is induced and tRA
synthesis is reduced, whereas under conditions of reti-
noid deficiency the opposite situation occurs (Fig. 3).
Utilization of retinyl esters
In human skin in vivo, retinol esterifying activity is four-
fold greater, on a per cell basis, in keratinocytes in the
bottom layer of the epidermis than in keratinocytes in up-
per layers (45). This suggests that retinoid levels are
higher in the lower epidermis, which is close to the nutri-
ent supply from capillaries in the high dermis, than in
the upper epidermis. It also suggests that all-trans retinol
stores, in the form of retinyl esters, are greater in kerati-
nocytes in lower epidermal layers than in upper layers.
Keratinocytes in the bottom layer of the epidermis mi-
grate through the upper cell layers toward the outside. As
they do so, they undergo maturation and terminal differ-
entiation near the skin surface. Retinyl ester synthesis by
keratinocytes in the bottom layer of the epidermis could
provide these cells with a source of all-trans retinol dur-
ing their migration and maturation. This scheme is con-
sistent with the observation that maturing keratinocytes
possess the capacity to metabolize all-trans retinol to its
active metabolite tRA (47).
tRA biosynthesis
Biosynthesis of tRA from all-trans retinol occurs in two
steps: all-trans retinol is oxidized to all-trans retinalde-
hyde, which is further oxidized to tRA (Fig. 3). Oxidation
of all-trans retinol to all-trans retinaldehyde is rate limit-
ing for tRA biosynthesis. Short-term topical treatment of
human skin with all-trans retinol results in histological
and molecular alterations that closely mimic those that
occur in response to tRA (44). These include increased
epidermal thickness due to increased keratinocytes pro-
liferation, widening of intercellular spaces, compaction of
the epidermal barrier, and induction of CRBP, CRABPII,
and retinoic acid 4-hydroxylase (see below). tRA is mini-
mally detectable in untreated and all-trans retinol-treated
human skin (44, 47a). Failure to detect significant accu-
mulation of tRA in all-trans retinol-treated skin stems
from two factors: 1) conversion of all-trans ret inol to all-
trans retinaldehyde is tightly regulated, and 2) tRA that
is formed is rapidly hydroxylated by retinoic acid 4-hy-
droxylase. In cultured human keratinocytes, which do not
express retinoic acid 4-hydroxylase activity, less than 1%
of added all-trans retinol is converted to tRA (48). This
low rate of conversion occurs despite large cellular accu-
mulation of all-trans retinol, indicating that enzymatic ca-
pacity, rather than substrate availability, limits tRA
synthesis. This limiting regulation occurs at the conver-
sion of all-trans retinol to all-trans retinaldehyde, be-
cause in cultured keratinocytes, significantly greater tRA
is formed from all-trans retinaldehyde than from all-trans
ret inol.
The observation that tRA and all-trans retinol elicit
similar responses but that all-trans retinol does so with-
out detectable increases in tRA levels indicates that en-
dogenously synthesized tRA is much more efficient than
exogenous tRA in activating retinoid pathways in human
skin. This difference likely reflects limitations in cellular
uptake and subsequent intracellular localization of exo-
genously applied tRA. These data suggest that all-trans
retinol may be a more efficient and natural way to deliver
tRA to the correct subcellular location within skin cells
than direct treatment with tRA. The finding that all-trans
retinol causes significantly less irritation, which is associ-
ated with retinoid excess, than tRA is consistent with this
concept (49).
14-Hydroxy-4, 14-retro-retinol and all-trans
3,4-didehydroretinol biosynthesis
In addition to converting all-trans retinol to retinyl esters
and tRA, human epidermis also synthesizes i4-hydroxy-
4,i4-retro-retinol (50). This metabolite of all-trans retinol
was first shown to be biologically active in B-lympho-
cytes, where it substitutes for all-trans retinol in main-
taining cell growth in culture (51). Addition of
i4-hydroxy-4,14-retro-retinol to cultured keratinocytes
does not alter their growth or differentiation. Similarly,
topical treatment of human skin in vivo with 14-hydroxy-
4,14-retro-retinol causes no discernible cellular or mo-
lecular alterations (E. A. Duell, S. Kang, G. J. Fisher,
and J. J. Voorhees, unpublished results). Therefore, al-
though human skin possesses the capacity to synthesize
i4-hydroxy-4,i4-retro-retinol, the biological role of this
retinoid in human skin remains obscure. Human skin
also synthesizes all-trans 3,4-didehydroretinol (vitamin
A2) and its esters from all-trans retinol. The functional
significance of this metabolic pathway is unknown.
Reference numbers are shown in parentheses. 5E. A. Duell, X.-Y. Li, C. J. Fisher. j. J. Voorhees, unpublished results
C. J.Fisher,J.J.Voorhees, unpublished results.
tRA hydroxylation
As mentioned, tRA in human skin is catabolized primar-
ily to 4-hydroxy tRA (52). 4-Hydroxy tRA binds RARs
with at least 100-fold less affinity (18, 53) and is 10-fold
less potent in inducing retinoid responses in human
keratinocytes and mouse skin than tRA (54). The gene
encoding tRA 4-hydroxylase in human skin is unknown;
however, its enzymatic properties, measured in human
skin microsomes, are characteristic of members of the cy-
tochrome P-450 superfamily (52). These include depend-
ence on NADPH and inhibition by carbon monoxide and
azole compounds. Several known P-450 isoforms that hy-
droxylate tRA at the C4 position can be distinguished
from human skin tRA 4-hydroxylase by substrate speci-
ficity. Human skin tRA 4-hydroxylase is highly specific
for tRA. It does not act on other retinoids, including all-
trans retinol, all-trans retinaldehyde, and 9-cit and 13-cit
retinoic acid (20), or on other nonretinoid substrates util-
ized by members of the 1A, 2B, 2C, 2D, 2E, 3A, 4A, 4,
and 5 cytochrome P-450 subfamilies. This strict substrate
specificity is similar to that displayed by other members
of the cytochrome P-450 family that participate in steroid
hormone metabolism.
In untreated human skin, tRA 4-hydroxylase activity is
minimally detectable. Activity is induced fivefold, how-
ever, after topical treatment with tRA (52) (Fig. 3). tRA
4-Hydroxylase activity is also induced in skin treated
with 9-cit retinoic acid, 13-cit retinoic acid, and all-trans
retinol.
Induction of tRA 4-hydroxylase by all-trans retinol is
also likely mediated by tRA, which is formed by oxida-
tion of all-trans retinol. Note that cellular and molecular
responses of human skin to all-trans retinol are synergis-
tically enhanced by liarozole, which inhibits tRA 4-hy-
droxylase (55). Thus, tRA 4-hydroxylase seems to
function physiologically by regulating levels of endo-
genously synthesized tRA in human skin, in addition to
its role in catabolizing pharamacological levels of exoge-
nous tRA. Synergy between liarozole and all-trans retinol
also supports the notion that actions of all-trans retinol in
skin are mediated through its conversion to tRA.
Autoregulation of tRA levels
Note that expression of the four currently characterized
proteins that control tRA homeostasis in human skin are
regulated by tRA (Fig. 3). These include CRBP, CRAB-
P11, LRAT, and tRA 4-hydroxylase. CRBP facilitates all-
trans retinol uptake and presents it to LRAT for storage
as retinyl ester (56). Similarly, CRABPII facilitates tRA
uptake and presents it to tRA 4-hydroxylase for inactiva-
tion (57, 58). CRBP and CRABPII also participate in
positive aspects of retinoid signaling. All-trans retinol
bound to CRBP (holo-CRBP) is a substrate for conversion
to tRA (59, 60), and apo-CRBP inhibits LRAT (56).
Thus, the ratio of apo- to holo-CRBP is an important de-
terminant regulating the balance between the oxidation
and estrification of all-trans retinol (57). In addition,
CRABPII may facilitate transport of tRA to the nucleus
(61). Transcription of both the CRBP and CRABPII
genes is positively regulated by RARs through RAREs in
their promoters. Although neither tRA 4-hydroxylase nor
LRAT has been cloned, it is tempting to speculate that
TABLE 1. Comparison of responses of keratinocytes to retinoid.s in culture vs. in vivo5
Response of Keratinocytes to Retinoids In culture In vivo
Proliferation-related responses
Growth Variable (64) Increased (1, 2, 27, 28, 72)
Keratins 5 Reduced (86) No effect (27, 28)
Keratin 14 Reduced (86) No effect (27, 28)
Keratin 6 Reduced (86) Increased (27,28)
Differentiation-related reponses
Keratin 1 Reduced (65) No effect(27,28)
Keratin 10 Reduced (65) No effect(27,28)
Type 1 transglutaminase Reduced (67, 68) Increased (68)
Loricrin Reduced (69, 70) Increased (27, 28)
Involucrin No change (87) Increased (27)
Profilaggrin/Filaggrin Reduced (66) Increased (27,28)
Other
CRABPII No effect (26) Increased (26)
CRBP No effect(21) Increased (21)
RA 4-hydroxylase No effects’ Increased (52)
Collagenase induction No effect’ Reduced (39)
the genes for these two enzymes might also be directly
regulated by RARs. This would provide a common
mechanism for autoregulation of tRA levels (Fig. 3). Not
yet accounted for is regulation of all-trans retinol dehy-
drogenase, the rate-limiting enzyme in tRA biosynthesis.
Although cloning of this enzyme has been elusive, recent
cloning of a specific all-trans retinol dehydrogenase from
rat liver should substantially aid study of tRA biosynthe-
sis in skin (62, 63). At present, it is evident that tRA,
through coordinate regulation of retinoid binding proteins
and metabolic enzymes, orchestrates a dynamic balance
between its own synthesis and breakdown in human skin
(Fig. 3).
RESPONSES OF KERATINOCYTES TO
RETINOIDS IN VIVO AND IN CULTURE DIFFER
Retinoids suppress terminal differentiation in
cultured keratinocytes
There are major differences in responses to retinoids be-
tween keratinocytes in culture and in vivo. This has led
to some misconceptions concerning the physiological and
pharmacological effects of retinoids on keratinocytes in
vivo. Knowledge about differences between how keratino-
cytes respond to retinoids in culture vs. in vivo is made
possible by the accessibility of skin in vivo to exogenous
treatments and the relative ease with which it can be ob-
tained. Obviously, most other tissues, especially in hu-
mans, cannot be directly obtained for study. Table 1
compares several responses of keratinocytes to retinoids
in vivo and in culture. Paradoxically, retinoids often have
effects on cultured keratinocytes opposite from those on
keratinocytes in vivo. Differentiation of cultured keratino-
cytes can be divided into two sequential processes: 1)
commitment, marked by irreversible growth arrest, and 2)
functional differentiation, marked by expression of differ-
entiation-specific gene products. Retinoids act predomi-
nantly on the latter process to inhibit expression of the
differentiated phenotype (64). This is manifested as inhi-
bition of expression of differentiation-associated keratins
1 and 10 (65), filaggrin (66), and several gene products
associated with formation of the epidermal barrier (i.e.,
cross-linked envelopes) (67-71). Cross-linked envelopes
consist of a network of specific proteins (loricrin, involu-
cnn, cornifin) localized beneath the plasma membrane
that are stabilized by cross-linkages with y-glutamyl cys-
teinyl isopeptides. These protein cross-links are catalyzed
by type I and type III transglutaminases. The highly in-
soluble cross-linked envelope serves as a critical struc-
tural element in the protective barrier of skin.
Retinoids alter keratinocyte growth and
differentiation in vivo
In contrast, in vivo retinoids stimulate keratinocyte prolif-
eration. This occurs with both topical and oral retinoid
administration, indicating it is not simply a reaction to ir-
ritation caused by topical treatment. In skin, keratino-
cytes in the bottom (basal) layer of the epidermis are ca-
pable of cell division. Basal keratinocytes migrate to
upper (suprabasal) cell layers, and in so doing become
committed to differentiation and lose the ability to divide.
Whereas the effects of retinoids on keratinocyte growth in
culture are variable and typicaly modest, retinoids con-
sistently and strongly stimulate keratinocyte growth in
vivo. Retinoids stimulate division of basal keratinocytes
in vivo, which migrate upward and differentiate (1, 2,
72). Growth stimulation by retinoids is dose dependent
and results in increased numbers of suprabasal layers,
populated by keratinocytes that exhibit precocious ex-
pression of differentiation-specific gene products (27, 28,
68). These suprabasal keratinocytes form cross-linked en-
velopes and are sloughed off at the skin surface. Expres-
sion of keratin pairs 5 and 14 (made in basal
keratinocytes) and of keratins 1 and 10 (made in supra-
basal keratinocytes) is not altered by retinoid treatment
in vivo (27, 28). Thus, retinoids do not suppress keratino-
cyte terminal differentiation in vivo, as is observed in
culture. Rather, in vivo retinoids stimulate keratinocyte
growth and modulate differentiation, and thereby modify
the finely tuned balance between these two cellular proc-
esses. Retinoids do cause a modest decrease in barrier
function. However, this effect does not reflect simply in-
hibition of cross-linked envelope formation, but rather
more complex alterations involving increased keratinocyte
turnover and altered differentiation.
Retinoid receptor-dependent gene regulation in
vivo vs. in culture
In addition to disparate effects on keratinocyte growth
and differentiation in vivo vs. in culture, several genes
involved in retinoid metabolism that are retinoid induc-
ible in vivo are not responsive to retinoids in culture.
These include cellular retinoic acid binding protein II,
cellular retinol binding protein, and retinoic acid 4-hy-
droxylase. Note that the former two genes contain RAREs
in their promoters (30, 31), and are therefore regulated
directly by nuclear retinoic acid receptors.
Transactivation vs. transrepression
Why do keratinocytes in vivo and in culture exhibit such
strikingly dissimilar responses to retinoids? Accumulating
evidence for cross-talk among retinoid and other signal-
ing pathways, most notably transcription factor AP-1, may
offer at least a partial explanation. Cross-talk among reti-
noid and other signaling pathways raises the possibility
that responses of keratinocytes to retinoids may differ de-
pending on the prevailing context of other signals. For
example, under conditions of AP-1 activation, the pre-
dominant action of retinoids may be transrepression (i.e.,
inhibition of AP-1-driven responses), whereas under ba-
sal AP-1 conditions, transactivation of retinoid responsive
genes may predominate. Likely candidates for signals
present in vivo that are not present in culture are those
derived from the dermis, which is known to have trophic
influences on keratinocyte growth and maturation (73).
These include soluble mediators such as keratinocyte
growth factor (74) and insulin-like growth factor (75), as
well as physical interactions of basal keratinocytes with
structural proteins of the basement membrane.
Nuclear retinoid receptor levels
In addition to differences in dermal influences, keratino-
cytes in vivo and in culture differ in their levels of nu-
clear retinoid receptors. Cultured keratinocytes express
approximately fourfold fewer retinoic acid receptors and
sevenfold fewer retinoid X receptors than keratinocytes in
vivo (G. J. Fisher and J. J. Voorhees, unpublished re-
sults). Reduced receptor expression may limit the ability
of cultured keratinocytes to respond to retinoids com-
pared with keratinocytes in vivo. Clearly, unraveling the
mechanisms that account for differences in retinoid re-
sponses between keratinocytes in vivo and in culture is a
formidable proposition. It is equally clear that significant
differences do exist, and that responses of cultured kerat-
inocytes to retinoids cannot readily be extrapolated to
keratinocytes in vivo.
PERSPECTIVES
Although probably more is known about retinoid physiol-
ogy and pharmacology in skin than in any other single or-
gan, much remains to be learned. The weight of evidence
indicates that retinoid actions are primary mediated by
retinoid receptors. If so, then how do retinoid receptors
modulate cutaneous growth and differentiation? Given
that retinoid receptors are transcription factors, this must
be accomplished through regulation of gene expression.
Knowledge of how retinoid receptors regulate gene ex-
pression and what genes are regulated is therefore criti-
cally important to unraveling how retinoids exert their
effects in skin.
Based on current information, three distinct mecha-
nisms exist through which retinoid receptors modulate
gene expression: 1) transactivation through direct binding
to RARE in target gene promoters, thereby stimulating
basal transcriptional machinery (Fig 2, upper panel), 2)
transrepression of AP-1 (and other transcription factors?)
through protein-protein interactions (Fig. 2, middle
panel), and 3) competition with other nuclear receptors
(i.e., vitamin D, thyroid hormone, and peroxisome prolif-
erator activated) for heterodimerization with RXR (Fig. 2,
lower panel).
Transactivation and target genes
Of these three mechanisms, transactivation of RARE-con-
taining genes is the best established. At present, only
three RARE-containing genes-CRABPII, CRBP, and
keratin 6-have been demonstrated to be regulated by
tRA in skin. Because the products of these genes are not
effectors, they cannot account for the pleiotypic effects of
retinoids in skin. It is likely, therefore, that additional
RARE-regulated genes will be identified that encode for
proteins that more directly function to modulate cutane-
ous growth and differentiation. Possible candidates for
such gene products include transcription factors, cell cy-
cle components, kinases and phosphatases involved in
cellular signaling, or master regulators of the above.
Transrepression
The second mechanism through which RARs modulate
gene expression is transrepression of AP-1. Transrepres-
sion of AP-1 by tRA has been established as a pharma-
cological phenomenon. Whether it also operates as a
physiological regulatory mechanism is unknown. How-
ever, one could imagine that under conditions of AP-1
activation, i.e., growth, differentiation, or stress,
transrepression of AP-1 by RARs could act as a negative
regulatory mechanism to protect against the conse-
quences of inappropriately prolonged AP-1 activation.
For this to occur would require coordinate regulation of
tRA levels, through synthesis and/or uptake, and AP-1
activation, as transrepression is tRA-dependent. Whether
this happens remains to be explored.
Retinoid X receptor heterodimerization
The third mechanism of RAR-mediated gene regulation is
through competition of RARs with other nuclear receptors
for heterodimenization with RXR. Sequestration of RXRs
through heterodimerization with RARs could act to regu-
late negatively the activity of other nuclear receptors that
partner with RXR in favor of RAR-mediated responses.
Conversely, other RXR partners could negatively influ-
ence RAR activity. Competition among RARs and other
nuclear receptors for RXR and/or its associated cofactors
would be dictated by relative receptor levels and their af-
finities for RXR. Although such competition is theoreti-
cally possible, it has yet to be demonstrated in vivo.
Effects of receptor selective synthetic retinoids
Retinoids have been shown to be efficacious for several
skin conditions, including psoriasis, acne, icthyosis, pho-
toaging, and cancer, and to reduce skin atrophy caused
by corticosteroid treatment for inflammatory diseases
(76). Further development of synthetic retinoids for these
and other conditions holds great promise. Skin is a thera-
peutic target particularly well suited for retinoids because
of the possibility of topical application. Typically, sys-
temic absorption of retinoids from topical administration
is slow, thus minimizing the likelihood of unwanted sys-
temic side effects. Retinoids that are selective for RAR
subtype and for either RAR or RXR have been described
(34, 77, 78). Thus, in principle it is possible to design
retinoids that exhibit a broad range of biological activi-
ties. Given this possibility, how can these retinoids be
best put to practical advantage? Part of the answer to this
obviously complex question lies in whether RAR sub-
types possess functional specificity. Although studies
with transfected receptors acting over isolated response
elements support the view that they do, this remains to be
demonstrated in vivo.
RAR-y is the predominant RAR in skin. It is expressed
in keratinocytes throughout the epidermis and in fi-
broblasts in the dermis (79). One would expect, therefore,
that RAR-y-specific retinoids would have potent effects
on skin cells. One drawback to their use, however, is the
possibility of enhanced skin irritation and scaling, inas-
much as the intensity of these side effects of retinoids
correlates with their ability to activate RAR-? (80).
Whether RAR-a, which is expressed at approximately
one-tenth the level of RAR-y, also mediates side effects
is not known. Treatment of mouse skin with an RXR se-
lective retinoid was without detectable effect (23), sug-
gesting that RXR homodimers do not transactivate genes
in skin. In contrast, RXR selective ligands can potentiate
the actions of RXR-containing heterodimers in the pres-
ence of the ligand for the partner receptor.
Anti-AP- 1 synthetic retinoids
Perhaps the most promising novel therapeutic uses of
synthetic retinoids for skin diseases are as AP-1 antago-
nists. Immune cell activation and inflammation are typi-
cal features of many common skin diseases. Transcription
of several lymphokine and cytokine genes, which drive
the hyperplastic inflammatory response in skin, is regu-
lated by transcription factors AP-1 and NF-KB. The anti-
inflammatory effects of corticosteroids, which are a
mainstay of treatment for inflammatory skin diseases, are
likely attributable to their ability to inhibit these tran-
scription factors. Recent evidence indicates that reti-
noids, like corticosteroids, are able to inhibit AP-1 (35,
36). Unlike corticosteroids, however, retinoids do not in-
hibit NF-KB (81, 82). Retinoid inhibition of AP-1 is me-
diated by the interaction of RAR and RXR with jun and
fos, which compose AP-1, to form an inactive complex.
Thus, RARs possess two ligand-dependent functions:
transactivation of genes containing RAREs, and
transrepression of genes containing AP-1 response ele-
ments. tRA activates both functions. Some synthetic reti-
noids, however, are able to distinguish between these two
functions. Synthetic retinoids have been described that
exhibit potent AP-1 transrepression, but negligible RARE
transactivation, and vice versa (83). Such retinoids
should be useful in elucidating the roles of transactiva-
tion vs. transrepression in mediating physiological and
pharmacological responses of skin to retinoids. In addi-
tion, retinoids that preferentially transrepress AP-1 may
prove to be useful anti-inflammatory and antiproliferative
therapeutic agents. Such retinoids also offer the intrigu-
ing possibility of reduced side effects, compared to con-
ventional retinoids, due to their inability to stimulate
RAR (RAR-y is a mediator of retinoid irritation) transac-
tivation activity.
Negative regulation of retinoid signaling
Finally, orphan receptors such as chicken ovalbumin up-
stream promoter-transcription factor (COUP-TF) and
TAK1 may function as negative regulators of retinoid sig-
naling (84, 85). COUP-TF, which is expressed in skin,
inhibits expression of RAR-dependent reporter genes in
human keratinocytes. This most likely occurs as a result
of competition of COUP-TF with RARs for RARE bind-
ing. COUP-TF binds not only to RAREs, but also to other
direct repeat response elements recognized by vitamin D,
thyroid hormone, and peroxisome proliferator-activated
receptors. These receptors each function as heterodimers
with RXR. Therefore, COUP-TF, which binds to DNA as
homodimers, may influence the activities of the subset of
nuclear receptors that partner with RXR. Obviously,
there is much to learn about the function and regulation
of COUP-TF and other orphan receptors in the skin. In-
formation gained from these studies of the function and
regulation of COUP-TF and other orphan receptors in the
skin will likely provide important new insights into the
physiology and pharmacology of retinoids in skin. []
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